Ciprofloxacin Resistance in an ICU: Selection or Instruction?
In a 20-bed intensive care unit, 60% of Pseudomonas aeruginosa isolates were resistant to ciprofloxacin in January. By December, after a policy of empirical ciprofloxacin for all ventilator-associated pneumonia (VAP), resistance reached 88%. The ciprofloxacin MIC50 rose from 0.5 to 8 µg/mL. A resident says the bacteria learned to resist because they were exposed. The infection-control team proposes cycling antibiotics every 3 months and restricting ciprofloxacin. A molecular study finds a gyrA mutation in resistant isolates; no resistance plasmid was found. The unit has 12 new VAP cases per month, a limited supply of colistin, and no rapid susceptibility testing at night. Hand-hygiene compliance is 55%. Most patients have endotracheal tubes and urinary catheters. The hospital's antibiotic committee meets monthly, and there is no antimicrobial stewardship pharmacist.
1. Explain the rise in resistance in evolutionary terms. Why is the statement that the bacteria 'learned' to resist incorrect?
Read the worked answer
The rise is natural selection, not learning. In any large bacterial population, rare mutants with reduced drug binding already exist or arise by mutation. Ciprofloxacin kills susceptible cells; a gyrA mutation alters DNA gyrase so the drug binds less well, and those mutants survive, reproduce, and pass the mutation vertically to daughter cells. The MIC50 shift from 0.5 to 8 µg/mL and the rise from 60% to 88% resistance are exactly what selection predicts when the same drug is used empirically. The bacteria did not acquire resistance because they were exposed; exposure merely changed the frequency of variants. The absence of a resistance plasmid suggests chromosomal mutation rather than horizontal transfer, although plasmids can be missed. The key point is that the antibiotic is the selective pressure, not the instructor.
2. Evaluate the proposed antibiotic cycling. What conditions make cycling more or less likely to work, and what else should be done?
Read the worked answer
Cycling can work only under specific conditions: resistance must carry a fitness cost, the drugs must not share cross-resistance, and the population must not already be multidrug-resistant. In this ICU, Pseudomonas is notorious for cross-resistance and for acquiring multiple mechanisms, so 3-month cycling alone is unlikely to reverse 88% resistance. It may even create a fluctuating selective environment. The stronger plan is antimicrobial stewardship: restrict empirical ciprofloxacin, use culture-guided therapy, shorten treatment, and de-escalate. Infection control matters equally: hand hygiene is only 55%, and endotracheal tubes and urinary catheters are portals for infection. A rapid susceptibility test at night would reduce blind prescribing. Colistin should be reserved, not cycled casually, because resistance would leave few options.
3. If colistin is the last resort, why might combining it with a beta-lactam reduce the emergence of resistance? What evolutionary principle is involved?
Read the worked answer
Combining colistin with a beta-lactam attacks two different targets, so a bacterium would need two independent resistance mechanisms to survive. If the mutation rate for each mechanism is low, the chance of a single cell having both is the product of the two probabilities, which is much smaller than either alone. The combination also narrows the mutant selection window and can be synergistic. This is the evolutionary principle of reducing the probability of simultaneous resistance. However, the beta-lactam must be active against the isolate; combining two drugs that are both ineffective adds toxicity without benefit. Susceptibility testing and dose optimization are therefore essential.